A new index in the follow-up of arrhythmia of Coronavirus Disease-2019 (COVID-19) patients receiving Hydroxychloroquine and Azithromycin therapy; index of cardiac electrophysiological balance

İsa Ardahanlı; Onur Akhan; Ramazan Aslan; Mehmet Celik; Okan Akyüz

doi:10.7197/cmj.870158

EN

A new index in the follow-up of arrhythmia of Coronavirus Disease-2019 (COVID-19) patients receiving Hydroxychloroquine and Azithromycin therapy; index of cardiac electrophysiological balance

Abstract

Objective: Index of cardiac electrophysiological balance (iCEB) is a relatively new electrocardiographic (ECG) parameter that shows the balance between ventricular depolarization and repolarization, thus providing more information than other conventional ECG parameters such as QT and corrected QT (cQT) intervals. This study aimed to evaluate the condition of iCEB with the treatment of hydroxychloroquine and azithromycin used in COVID-19 patients.

Method: The study was designed as cross-sectional and descriptive. Sixty three (52 male, 28.4 ± 10.7 years) COVID-19 patients with mild symptoms who received hydroxychloroquine and azithromycin treatment between 30 March and 30 June 2020 were included in the study. iCEB and corrected iCEB (iCEBc) values were calculated by dividing the respective QT and cQT intervals by the QRS duration.

Results: In the study group, the mean PR, QRS, QT and cQT intervals were similar between groups. While heart rate was significantly higher before treatment, iCEB and iCEBc increased significantly after treatment.

Conclusions: Our study did not observe a significant difference in QT and cQT intervals with hydroxychloroquine and azithromycin treatment in COVID-19. Still, there was a significant increase in the iCEB and iCEBc. We believe that the cardiac electrophysiological balance index can be used to monitor arrhythmias in patients undergoing short-term treatment at COVID -19.

Keywords

Kaynakça

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565‐574. doi:10.1016/S0140-6736(20)30251-8.
WHO Novel Coronavirus (2019-nCoV) Situation Report - 1 21 January 2020. Available from https://www.who.int/docs/default-source/coronaviruse/situationreports/20200121-sitrep-1-2019 ncov.pdf?sfvrsn=20a99c10_4. (Accessed 28 Feb. 2020).
World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March. Available from URL: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020. (Accessed March 2020).
World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard, Data last updated: 2020/11/14, 3:32pm CET. (Accessed 18 Jan. 2021)
Ahmet Aktaş, Burak Tüzün, Rukiye Aslan, Koray Sayin & Hilmi Ataseven (2020) New anti-viral drugs for the treatment of COVID-19 instead of favipiravir, Journal of Biomolecular Structure and Dynamics, DOI: 10.1080/07391102.2020.1806112
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(16). doi:10.1038/s41421-020-0156-0
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732-739. doi:10.1093/cid/ciaa237
Aktas, A., Tuzun, B., Taskin, A. H., Sayin, K., & Ataseven, H. (2020). How do arbidol and its analogs inhibit the SARS-CoV-2?. Bratislavske lekarske listy, 121(10), 705-711.

Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72‐73. doi:10.5582/bst.2020.01047
Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, et al. Evaluation of Ebola Virus Inhibitors for Drug Repurposing. ACS Infect Dis. 2015;1(7):317‐326. doi:10.1021/acsinfecdis.5b00030
Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT, Sandoval-Espinosa C, et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A. 2016;113(50):14408‐14413. doi:10.1073/pnas.1618029113
Trac MH, McArthur E, Jandoc R, Dixon SN, Nash DM, Hackam DG, et al. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. CMAJ. 2016;188(7):E120‐E129. doi:10.1503/cmaj.150901
Choi Y, Lim HS, Chung D, Choi JG, Yoon D. Risk evaluation of zzithromycin-induced QT prolongation in real-world practice. Biomed Res Int. 2018;2018:1574806. doi:10.1155/2018/1574806
Frommeyer G, Fischer C, Ellermann C, Dechering DG, Kochhäuser S, Lange PS, et al. Additive proarrhythmic effect of combined treatment with QT-prolonging agents. Cardiovasc Toxicol. 2018;18(1):84‐90. doi:10.1007/s12012-017-9416-0
Bakhshaliyev N, Uluganyan M, Enhos A, Karacop E, Ozdemir R. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients. J Electrocardiol. 2020;62:59-64. doi:10.1016/j.jelectrocard.2020.08.008
Lu HR, Yan GX, Gallacher DJ. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs). J Pharmacol Toxicol Methods. 2013;68(2):250‐259. doi:10.1016/j.vascn.2013.01.003
Robyns T, Lu HR, Gallacher DJ, Garweg C, Ector J, Willems R, et al. Evaluation of index of cardio-electrophysiological balance (iCEB) as a new biomarker for the identification of patients at increased arrhythmic risk. Ann Noninvasive Electrocardiol. 2016;21(3):294‐304. doi:10.1111/anec.12309
Wang X, Zhang L, Gao C, Zhu J, Yang X. Tpeak-Tend/QT interval predicts ST-segment resolution and major adverse cardiac events in acute ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention. Medicine (Baltimore). 2018 Oct;97(43):e12943. doi: 10.1097/MD.0000000000012943. PMID: 30412109; PMCID: PMC6221564.
Ardahanli, I., & Celik, M. Comparison of Tp-e interval, QTc interval and Tp-e/QTc ratios between non-diabetic and prediabetic population. Ann Med Res 2020;27(12):3117-22. DOI: 10.5455/annalsmedres.2020.09.949
Nafakhi H, Al-Mosawi AA, Alareedh M, Al-Nafakh HA. Index of cardiac electrophysiological balance and transmural dispersion of the repolarization index relationships with pericardial fat volume and coronary calcification. Biomark Med. 2018;12(4):321‐328. doi:10.2217/bmm-2017-0187
Özdemir L, Sökmen E. Effect of habitual cigarette smoking on the index of cardiac electrophysiological balance in apparently healthy individuals. J Electrocardiol. 2020;59:41‐44. doi:10.1016/j.jelectrocard.2020.01.003
Hemmeryckx B, Feng Y, Frederix L, Lox M, Trenson S, Vreeken R, et al. Evaluation of cardiac arrhythmic risks using a rabbit model of left ventricular systolic dysfunction. Eur J Pharmacol. 2018;832:145‐155. doi:10.1016/j.ejphar.2018.05.026
Cipriani A, Zorzi A, Ceccato D, Capone F, Parolin M, Donato F, et al. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin. Int J Cardiol. 2020;316:280-284 doi:10.1016/j.ijcard.2020.05.036
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061‐1069. doi:10.1001/jama.2020.1585

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

İsa Ardahanlı ^*
0000-0002-9309-803X
Türkiye

Onur Akhan
0000-0003-4440-9599
Türkiye

Ramazan Aslan
0000-0002-1255-7880
Türkiye

Mehmet Celik
0000-0001-7364-370X
Türkiye

Okan Akyüz
0000-0003-2460-9577
Türkiye

Yayımlanma Tarihi

31 Mart 2021

Gönderilme Tarihi

28 Ocak 2021

Kabul Tarihi

5 Şubat 2021

Yayımlandığı Sayı

Yıl 2021 Cilt: 43 Sayı: 1

DOI

https://doi.org/10.7197/cmj.870158

IZ

https://izlik.org/JA79RA84DF

Kaynak Göster

RIS / Bibtex

AMA

1.Ardahanlı İ, Akhan O, Aslan R, Celik M, Akyüz O. A new index in the follow-up of arrhythmia of Coronavirus Disease-2019 (COVID-19) patients receiving Hydroxychloroquine and Azithromycin therapy; index of cardiac electrophysiological balance. CMJ. 2021;43(1):1-7. doi:10.7197/cmj.870158